# Release (release) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/release

> Release (release), sponsored by Cingulate Inc. (CING), received a complete response letter from the FDA; the decision is dated November 10, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is Release (release) FDA approved?

Not as of November 16, 2026. Release (release), sponsored by Cingulate Inc. (CING), received a complete response letter from the FDA; the decision is dated November 10, 2026. SEC Form 8-K: "November 10, 2026, Cingulate Inc. (Company) issued a press release announcing that its Chairman and CEO, Shane J. Schaffer, in an interview on Innovators with Jane King discusses the Company's ongoing efforts to address the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding the CTx-1301 new drug application (NDA), progress made to date, and the anticipated timeline for NDA resubmission." [Calendar and source filings](https://sec-api.dev/pdufa/release)

Source: SEC Form 8-K, accession 0001493152-26-050870, https://www.sec.gov/Archives/edgar/data/1862150/000149315226050870/form8-k.htm (retrieved 2026-11-12). Last confirmed 2026-11-10. Cite: https://sec-api.dev/pdufa/release#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | Release (release) |
| Codes |  |
| Sponsor | Cingulate Inc. (CING) https://sec-api.dev/companies/cing/catalysts |
| Indications | attention deficit/hyperactivity |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### February 26, 2024: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-12T03:48:32.313Z, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA217002_20240226.pdf%22

### July 31, 2025: NDA/BLA submission

- Status: completed. Date confidence: exact.
- First seen 2025-08-19, last confirmed 2025-08-19.
- Press release filed with the SEC (EX-99) (accession 0001641172-25-024741): "July 31, 2025, Cingulate submitted its NDA to the FDA for CTx-1301, a novel, extended-release tablet formulation of dexmethylphenidate designed to deliver a fast onset, entire active-day efficacy, and a smooth pharmacokinetic profile with a single dose, addressing major limitations of current ADHD therapies." https://www.sec.gov/Archives/edgar/data/1862150/000164117225024741/ex99-1.htm

### October 14, 2025: NDA/BLA acceptance

- Status: completed. Date confidence: exact. Indication: attention deficit/hyperactivity.
- First seen 2025-10-14, last confirmed 2025-10-14.
- SEC Form 8-K (accession 0001493152-25-017931): "October 14, 2025, Cingulate Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration (the "FDA") has accepted for review the New Drug Application ("NDA") for CTx-1301 (dexmethylphenidate), the Company's lead candidate for the treatment of attention deficit/hyperactivity ("ADHD") for children and adults." https://www.sec.gov/Archives/edgar/data/1862150/000149315225017931/form8-k.htm

### May 29, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-06-02, last confirmed 2026-11-16T22:20:01.192Z.
- FDA complete response letter database: "We have completed our review of this application, as amended, and have determined that we cannot approve this application in its present form." https://api.fda.gov/transparency/crl.json?search=file_name:%22CRL_NDA220283_20260529_Redacted.pdf%22
- SEC Form 8-K (accession 0001493152-26-026760): "June 2, 2026, Cingulate Inc. (the "Company") issued a press release announcing that the U.S. Food and Drug Administration ("FDA") has issued a Complete Response Letter ("CRL") for its New Drug Application for CTx-1301 (dexmethylphenidate" https://www.sec.gov/Archives/edgar/data/1862150/000149315226026760/form8-k.htm

### November 10, 2026: complete response letter (CRL)

- Status: completed, complete response letter. Date confidence: exact.
- First seen 2026-11-10, last confirmed 2026-11-10.
- SEC Form 8-K (accession 0001493152-26-050870): "November 10, 2026, Cingulate Inc. (Company) issued a press release announcing that its Chairman and CEO, Shane J. Schaffer, in an interview on Innovators with Jane King discusses the Company's ongoing efforts to address the U.S. Food and Drug Administration's (FDA) Complete Response Letter (CRL) regarding the CTx-1301 new drug application (NDA), progress made to date, and the anticipated timeline for NDA resubmission." https://www.sec.gov/Archives/edgar/data/1862150/000149315226050870/form8-k.htm

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/release.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Release (release) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/release

```bibtex
@misc{secapidev_pdufa_release_20261116,
  title        = {Release (release) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/release}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_release_20261116","title":"Release (release) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/release","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
